Immune Cells and RBCs Derived from Human Induced Pluripotent Stem Cells: Method, Progress, Prospective Challenges

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2024 Jan 22

PMID 38250324

Authors

Jin-He Jiang

Ru-Tong Ren

Yan-Jie Cheng

Xin-Xin Li

Gui-Rong Zhang

Affiliations

Soon will be listed here.

Abstract

Blood has an important role in the healthcare system, particularly in blood transfusions and immunotherapy. However, the occurrence of outbreaks of infectious diseases worldwide and seasonal fluctuations, blood shortages are becoming a major challenge. Moreover, the narrow specificity of immune cells hinders the widespread application of immune cell therapy. To address this issue, researchers are actively developing strategies for differentiating induced pluripotent stem cells (iPSCs) into blood cells . The establishment of iPSCs from terminally differentiated cells such as fibroblasts and blood cells is a straightforward process. However, there is need for further refinement of the protocols for differentiating iPSCs into immune cells and red blood cells to ensure their clinical applicability. This review aims to provide a comprehensive overview of the strategies and challenges facing the generation of iPSC-derived immune cells and red blood cells.

References

Alasoo K, Martinez F, Hale C, Gordon S, Powrie F, Dougan G . Transcriptional profiling of macrophages derived from monocytes and iPS cells identifies a conserved response to LPS and novel alternative transcription. Sci Rep. 2015; 5:12524. PMC: 4519778. DOI: 10.1038/srep12524. View

Focosi D, Amabile G . Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside. Cells. 2017; 7(1). PMC: 5789275. DOI: 10.3390/cells7010002. View

Maeda T, Nagano S, Ichise H, Kataoka K, Yamada D, Ogawa S . Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity. Cancer Res. 2016; 76(23):6839-6850. DOI: 10.1158/0008-5472.CAN-16-1149. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Miharada K, Hiroyama T, Sudo K, Nagasawa T, Nakamura Y . Efficient enucleation of erythroblasts differentiated in vitro from hematopoietic stem and progenitor cells. Nat Biotechnol. 2006; 24(10):1255-6. DOI: 10.1038/nbt1245. View

Yanagimachi M, Niwa A, Tanaka T, Honda-Ozaki F, Nishimoto S, Murata Y . Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions. PLoS One. 2013; 8(4):e59243. PMC: 3616072. DOI: 10.1371/journal.pone.0059243. View

Aquino-Jarquin G . Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing. Mol Genet Metab. 2021; 134(1-2):77-86. DOI: 10.1016/j.ymgme.2021.08.002. View

Shankar K, Capitini C, Saha K . Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies. Stem Cell Res Ther. 2020; 11(1):234. PMC: 7298853. DOI: 10.1186/s13287-020-01741-4. View

Wang Z, McWilliams-Koeppen H, Reza H, Ostberg J, Chen W, Wang X . 3D-organoid culture supports differentiation of human CAR iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022; 29(4):651-653. DOI: 10.1016/j.stem.2022.03.007. View

10.

Sanber K, Savani B, Jain T . Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol. 2021; 195(5):660-668. DOI: 10.1111/bjh.17544. View

11.

Depil S, Duchateau P, Grupp S, Mufti G, Poirot L . 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020; 19(3):185-199. DOI: 10.1038/s41573-019-0051-2. View

12.

Ali H, Khan F, Musharraf S . Acyclovir induces fetal hemoglobin via downregulation of γ-globin repressors, BCL11A and SOX6 trans-acting factors. Biochem Pharmacol. 2021; 190:114612. DOI: 10.1016/j.bcp.2021.114612. View

13.

Yamada D, Iyoda T, Vizcardo R, Shimizu K, Sato Y, Endo T . Efficient Regeneration of Human Vα24 Invariant Natural Killer T Cells and Their Anti-Tumor Activity In Vivo. Stem Cells. 2016; 34(12):2852-2860. DOI: 10.1002/stem.2465. View

14.

Orlov D, Karkouti K . The pathophysiology and consequences of red blood cell storage. Anaesthesia. 2014; 70 Suppl 1:29-37, e9-12. DOI: 10.1111/anae.12891. View

15.

Lopez-Yrigoyen M, May A, Ventura T, Taylor H, Fidanza A, Cassetta L . Production and Characterization of Human Macrophages from Pluripotent Stem Cells. J Vis Exp. 2020; (158). DOI: 10.3791/61038. View

16.

Myers J, Miller J . Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2020; 18(2):85-100. PMC: 8316981. DOI: 10.1038/s41571-020-0426-7. View

17.

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

18.

van Wilgenburg B, Browne C, Vowles J, Cowley S . Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. PLoS One. 2013; 8(8):e71098. PMC: 3741356. DOI: 10.1371/journal.pone.0071098. View

19.

Kawamoto H, Masuda K, Nagano S . Regeneration of antigen-specific T cells by using induced pluripotent stem cell (iPSC) technology. Int Immunol. 2021; 33(12):827-833. DOI: 10.1093/intimm/dxab091. View

20.

Lapillonne H, Kobari L, Mazurier C, Tropel P, Giarratana M, Zanella-Cleon I . Red blood cell generation from human induced pluripotent stem cells: perspectives for transfusion medicine. Haematologica. 2010; 95(10):1651-9. PMC: 2948089. DOI: 10.3324/haematol.2010.023556. View